GRDNHealthcare · Medical Care FacilitiesThe 6 Wall Street analysts covering Guardian Pharmacy Services, Inc. hold a median 12-month price target of $50 — +10.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Guardian Pharmacy Services, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (93): Analysts have, on balance, been raising their forecasts.
Value (25): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GRDN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.0% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Oppenheimer | Maintains | Outperform | $43 → $49 |
| 17 June 2026 | B of A Securities | Maintains | Buy | — |
| 17 June 2026 | B of A Securities | Maintains | Buy | $42 → $47 |
| 17 June 2026 | Truist Securities | Maintains | Buy | — |
| 17 June 2026 | Truist Securities | Maintains | Buy | $43 → $47 |
| 7 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 27 Apr 2026 | B of A Securities | Initiates | Buy | — |
| 13 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 30 Mar 2026 | Jefferies | Initiates | Buy | — |
| 12 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 12 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 14 Jan 2026 | Stephens & Co. | Maintains | Overweight | — |
| 14 Nov 2025 | Truist Securities | Maintains | Buy | — |
| 10 Oct 2025 | Oppenheimer | Initiates | Outperform | — |
| 26 Sept 2025 | Truist Securities | Maintains | Buy | — |
| 19 May 2025 | Truist Securities | Reiterates | Buy | — |
| 11 Apr 2025 | Truist Securities | Maintains | Buy | — |
| 15 Nov 2024 | Truist Securities | Maintains | Buy | — |
| 22 Oct 2024 | Stephens & Co. | Initiates | Overweight | — |
| 21 Oct 2024 | Truist Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GRDN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Guardian Pharmacy Services, Inc. returned +70.3% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 17% of US stocks
Cheaper than 53% of US stocks
Cheaper than 8% of US stocks
Cheaper than 10% of US stocks
Higher than 32% of US stocks
Higher than 87% of US stocks
Higher than 24% of US stocks
Higher than 51% of US stocks
Higher than 58% of US stocks
Higher than 88% of US stocks
Higher than 96% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Guardian Pharmacy Services, Inc. has a market value of $2.8B and an enterprise value of $2.8B.
Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 2.2% year on year.
Net income over the same four quarters: $66.5M, a 4.5% net margin.
Diluted earnings per share, trailing twelve months: $1.03.
Free cash flow in the twelve months to 30 June 2026: $79.8M.
Guardian Pharmacy Services, Inc. spent $30.3M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 43.3×; forward P/E: 31.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Guardian Pharmacy Services, Inc. employs 3,600 people — $407K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Guardian Pharmacy Services, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Guardian Pharmacy Services, Inc. (NYSE: GRDN) has announced the acquisition of assets from Nautilus Pharmacy, a Tennessee-based pharmacy business. The announcement was made via Business Wire.
Why it matters — This acquisition expands Guardian Pharmacy Services' operations and market presence in Tennessee.
Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced it will participate in the Jefferies Healthcare Services Conference on Tuesday, September 15, 2026. President and CEO Fred Burke will take part in a fireside chat at 2:25 p.m. Central Standard Time, with a live audio webcast accessible to investors, analysts, media, and the public.
Why it matters — The company's participation and live webcast give GRDN watchers a scheduled opportunity to hear directly from its CEO about the business.
Guardian Pharmacy Services reported second-quarter revenue of $351.2 million, up 2% year over year, and adjusted EBITDA of $29.7 million, up 19%. The company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.
Why it matters — The results show Guardian maintained revenue growth and improved adjusted EBITDA despite ongoing drug-pricing headwinds from the IRA, giving those following GRDN a read on its profitability trajectory.
Guardian Pharmacy Services, Inc. (GRDN) held its Q2 2026 earnings call, and the transcript of that call has been published on Seeking Alpha. The excerpt provided identifies the headline and source but contains no details from the call itself.
Why it matters — A GRDN watcher would care because the earnings call transcript is a primary source for management's discussion of the company's latest quarterly financial performance and outlook.
Guardian Pharmacy Services reported Q2 earnings of $0.29 per share, surpassing the Zacks Consensus Estimate of $0.26 per share and up from $0.23 per share in the same period a year earlier. Revenues also topped estimates.
Why it matters — GRDN watchers would care because the company delivered results above analyst expectations and improved year-over-year earnings.
The 6 Wall Street analysts covering Guardian Pharmacy Services, Inc. have a median 12-month price target of $50, with estimates ranging from $47 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Guardian Pharmacy Services, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Guardian Pharmacy Services, Inc. 79 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Guardian Pharmacy Services, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (93 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +10.0% from the last close, and Ticker Nerd's factor model ranks Guardian Pharmacy Services, Inc. 79 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Guardian Pharmacy Services, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $50 over the next 12 months.
Guardian Pharmacy Services, Inc. returned +70.3% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Guardian Pharmacy Services, Inc. Class A Common Stock is the equity security of Guardian Pharmacy Services, a U.S.-based long-term care pharmacy services company headquartered in Atlanta, Georgia.
The most recent item we track (Business Wire, 1 Sept 2026): "Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy". Guardian Pharmacy Services, Inc. (NYSE: GRDN) has announced the acquisition of assets from Nautilus Pharmacy, a Tennessee-based pharmacy business. The announcement was made via Business Wire.
Guardian Pharmacy Services, Inc. Class A Common Stock is the equity security of Guardian Pharmacy Services, a U.S.-based long-term care pharmacy services company headquartered in Atlanta, Georgia. The company provides technology-enabled pharmacy solutions for residents of long-term care facilities, including assisted living facilities, behavioral health facilities, group homes, skilled nursing communities, and organizations serving individuals with intellectual and developmental disabilities. Its services combine clinical support, medication dispensing, and administration capabilities designed to help care teams manage complex medication regimens in lower-acuity settings. Guardian Pharmacy Services also offers data-driven tools and operational support that help local pharmacies coordinate workflows, monitor prescriptions, and improve service delivery across care communities. The Class A Common Stock represents ownership in a business focused on pharmacy services within the healthcare sector, supporting the infrastructure that connects medication management with resident care in long-term care environments.
CEO Mr. Fred P. Burke · 3,600 employees · United States · https://guardianpharmacy.com
